Last Updated: November 8, 2026

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE Drug Patent Profile

« Back to Dashboard


When do Bisoprolol Fumarate And Hydrochlorothiazide patents expire, and what generic alternatives are available?

Bisoprolol Fumarate And Hydrochlorothiazide is a drug marketed by Actavis Elizabeth, Apothecon, Aurobindo Pharma Ltd, Cadila, Chartwell Rx, Edenbridge Pharms, Epic Pharma Llc, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Mylan, Novitium Pharma, Teva, Unichem, Unique Pharm, and Watson Labs Teva. and is included in fifteen NDAs.

The generic ingredient in BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE is bisoprolol fumarate; hydrochlorothiazide. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bisoprolol Fumarate And Hydrochlorothiazide

A generic version of BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25th, 2000.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE?
  • What are the global sales for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE?
  • What is Average Wholesale Price for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE?
Summary for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
US Patents:0
Applicants:15
NDAs:15
Finished Product Suppliers / Packagers: 11
Raw Ingredient (Bulk) Api Vendors: 3
Patent Applications: 38
What excipients (inactive ingredients) are in BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE?BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE excipients list
DailyMed Link:BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE at DailyMed
Pharmacology for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

US Patents and Regulatory Information for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Unique Pharm BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 219489-002 Mar 24, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novitium Pharma BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 215562-002 Nov 4, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Watson Labs Teva BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 075469-003 Sep 25, 2000 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Mylan BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 075768-001 Sep 25, 2000 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novitium Pharma BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 215562-003 Nov 4, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Mylan BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE bisoprolol fumarate; hydrochlorothiazide TABLET;ORAL 075768-002 Sep 25, 2000 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.